Pemphigus: The promises of peptide immunotherapy

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 4, 2009, Pages 509-515

  Bisceglie, Maria Beatrice Di ^a   Lucchese, Alberta ^a   Crincoli, Vito ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Antigens; Immunotherapy; Pemphigus; Peptic vaccine; Rituximab

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CADHERIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DESMOCOLLIN; DESMOGLEIN; DESMOGLEIN 1; DESMOGLEIN 3; DESMOPLAKIN; GOLD; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; NICOTINAMIDE; PEPTIDE VACCINE; PREDNISONE; RITUXIMAB; STEROID; TETRACYCLINE;

ACANTHOLYSIS; AMINO ACID SEQUENCE; ANTIBODY TITER; CLINICAL CLASSIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG MEGADOSE; HERPETIFORM PEMPHIGUS; HUMAN; IGA PEMPHIGUS; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KERATINOCYTE; MORBIDITY; MORTALITY; NONHUMAN; PARANEOPLASTIC PEMPHIGUS; PATHOGENESIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN BIOPSY;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; CANCER VACCINES; DESMOGLEINS; HUMANS; IMMUNOTHERAPY; PEMPHIGUS; VACCINES, SUBUNIT;

EID: 70449126155     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970902814145     Document Type: Review

References (40)

1. Bystryn, J.C., Rudolf, J.L. Pemphigus. Lancet. 2005, 366 (9479), 61-73.
2. Femiano, F. Pemphigus vulgaris: Recent advances in our understanding of its pathogenesis. Minerva Stomatol. 2007, 56 (4), 215-223.
3. Shamim, T., Varghese, V.I., Shameena, P.M., Sudha, S. Pemphigus vulgaris in oral cavity: Clinical analysis of 71 cases. Med. Oral Pathol. Oral Cir. Bucal. 2008, 13 (10), 622-626.
4. Eversole, L.R., Kenney E.B., Sabes, W.R. Oral lesions as the initial sign in pemphigus vulgaris. Oral Surg. Oral Med. Oral Pathol. 1972, 33 (3), 354-361.
5. Regezi, J.A., Sciubba, J.J. Oral Pathology: Clinical Pathologic Correlations, 3rd ed. Philadelphia:W.B. Saunders, 1999, pp. 1-29.
6. Ioannides, D., Lazaridou, E., Rigopoulos, D. Pemphigus. J. Eur. Acad .Dermatol. Venereol. 2008, 22 (12), 1478-1496.
7. Jamora, M.J., Jiao, D., Bystryn, J.C. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. J. Am. Acad. Dermatol. 2003, 48 (6), 976-977.
8. Shirakata, Y., Amagai, M., Hanakawa, Y. et al. Lack involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J. Invest. Dermatol, 1998, 110 (1), 76-78.
9. Tong, J.C., Tan, T.W., Sinha, A.A., Ranganathan, S. Prediction of desmoglein-3 peptides reveals multiple shared T-cell epitopes in HLA DR4- and DR6-associated pemphigus vulgaris. BMC Bioinformatics, 2006, 18, 7.
10. Futei, Y., Amagai, M., Ishii, K., Kuroda-Kinoshita, K. et al. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J. Dermatol. Sci, 2001, 26 (1), 55-61.
11. Bhol, K., Natarajan, K., Nagarwalla, N. et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: A model for autoimmunity. Proc. Natl. Acad. Sci. U. S. A, 1995, 92 (11), 5239-5243.
12. Amagai, M., Hashimoto, T., Shimizu, N., Nishikawa, T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J. Clin. Invest. 1994,94 (1), 59-67.
13. Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch. Dermatol. Res. 2003, 295 (1), 2-11.
14. Calkins, C.C., Setzer, S.V., Jennings, J.M. et al. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J. Biol. Chem, 2006, 281 (11), 7623-7634.
15. Cirillo, N., Lanza, M., De Rosa A., et al. At least three phosphorylation events induced by pemphigus vulgaris sera are pathogenically involved in keratinocyte acantholysis. Int. J. Immunopathol. Pharmacol, 2008,21 (1), 189-195.
16. Chernyavsky, AI., Arredondo, J., Kitajima, Y. et al. Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: Characterization of novel signaling pathways downstream of pemphigus vulgaris antigens. J. Biol. Chem, 2007, 282 (18), 13804-13812.
17. Berkowitz, P., Chua, M., Liu, Z. et al. Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin. Am. J. Pathol, 2008, 173 (6), 1628-1636.
18. Yamamoto, Y., Aoyama, Y., Shu, E. et al. No activation of urokinase plasminogen activator by anti-desmoglein 3 monoclonal IgG antibodies in cultured human keratinocytes. J. Dermatol. Sci, 2007, 47 (2), 119-125.
19. Feliciani, C., Toto, P., Wang, B. et al. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp. Dermatol, 2003, 12 (4), 466-471.
20. Schuh, T., Besch, R., Braungart, E. et al. Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgarisinduced, acantholysis in human epidermis. Biol. Chem, 2003, 384 (2), 311-315.
21. Aoyama, Y., Owada, M.K., Kitajima, Y. A pathogenic autoantibody, pemphigus IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur. J. Immunol. 1999, 29 (7), 2233-2240.
22. de Bruin R., Caldelari, A., Williamson, L., et al. Plakoglobindependent disruption of the desmosomal plaque in pemphigus vulgaris. Exp. Dermatol, 2007, 16 (6), 468-475.
23. Williamson, L., Raess, NA., Caldelari, R. et al. Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J, 2006, 25 (14), 3298-3309.
24. Koch, J., Foekens, J., Timmermans, M. et al. Human VAT-1: A calcium-regulated activation marker of human epithelial cells. Arch. Dermatol. Res, 2003, 295 (5), 203-210.
25. Qian, Y., Diaz, L.A., Ye, J., Clarke S.H. Dissecting the anti- desmoglein autoreactive B cell repertoire in pemphigus vulgaris patients. J. Immunol, 2007, 178 (9), 5982-5990.
26. Takahashi, H., Amagai, M., Nishikawa, T. et al. Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris. J. Immunol, 2008, 181 (2), 1526-1535.
27. Veldman, C., Höhne, A., Dieckmann, D. et al. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J. Immunol, 2004, 172 (10), 6468-6475.
28. Nguyen, V.T., Ndoye, A., Grando, S.A. Novel human 9 acetylcholine receptor regulating keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity. Am. J. Pathol. 2000, 157(4), 1377-1391.
29. Nguyen, V.T., Arredondo, J., Chernyavsky, A.I. et al. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists. Arch. Dermatol, 2004, 140 (3), 327-334.
30. Chernyavsky, AI., Arredondo, J., Piser, T. et al. Differential coupling of M1 muscarinic and alpha7 nicotinic receptors to inhibition of pemphigus acantholysis. J. Biol. Chem, 2008, 283 (6), 3401-3408.
31. Mihai, S., Sitaru, C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J. Cell Mol. Med. 2007, 11 (3), 462-481.
32. Joly, P., Mouquet, H., Roujeau, J.C. et al. A single cycle of rituximab for the treatment of severe pemphigus. N. Engl. J. Med, 2007, 357 (6), 545-552.
33. Faurschou, A., Gniadecki, R. Two courses of rituximab (anti- CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int. J. Dermatol. 2008, 47 (3), 292-294.
34. Allen, K.J., Wolverton, S.E. The efficacy and safety of rituximab in refractory pemphigus: A review of case reports. J. Drugs Dermatol. 2007, 6 (9), 883-889.
35. Kanduc, D. Peptimmunology: Immunogenic peptides and sequence redundancy. Curr. Drug Discov. Technol, 2005, 2 (4), 239-244.
36. Hacker-Foegen, M.K., Janson, M., Amagai, M. Pathogenicity and epitope characteristics of anti-desmoglein-1 from pemphigus foliaceus patients expressing only IgG1 autoantibodies. J. Invest. Dermatol. 2003, 121 (6), 1373-1378.
37. Lucchese, A., Mittelman. A., Lin, M.S. et al. Epitope definition by protomic similarity analysis: Identification of the linear determinant of anti-Dsg3 MAb 5h10. J. Transl. Med, 2004, 2, 43.
38. Kanduc, D. Defining peptide sequences: From antigenicity to immunogenicity through redundancy. Curr. Pharmacogenomics, 2006, 4, 33-37.
39. Angelini, G., Bonamonte, D., Lin, MS. et al. Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3. J. Exp. Ther. Oncol, 2005, 5 (1), 1-7.
40. Angelini, G., Bonamonte, D., Lucchese, A. et al. Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: A case report. J. Transl. Med, 2006, 24, 4, 43.